> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Incyte’s Niktimvo Web Site is Misleading: FDA
- URL: https://www.fdaweb.com/incytes-niktimvo-web-site-is-misleading-fda/
- Published: 2026-04-24T12:00:00.000Z
- Updated: 2026-09-14T13:38:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161042

FDA has issued an [untitled letter](https://www.fda.gov/media/192125/download?attachment&ref=fdaweb.com) to Incyte Corp., warning that portions of the company’s consumer-facing Web site for Niktimvo (axatilimab-csfr) contain false or misleading promotional claims that violate federal law. CDER’s Office of Prescription Drug Promotion (OPDP) says it reviewed the drug’s branded site, including a “Niktimvo may offer fast and lasting responses” Web page and concluded that the materials misbrand the product.

At issue are claims suggesting the therapy delivers strong and rapid treatment responses in patients with chronic graft-versus-host disease (cGVHD). FDA says statements such as “most people achieved a response” and “75% of people experienced a response” could lead consumers to believe patients experienced complete responses, when in fact no complete responses were observed in clinical studies — only partial responses.

The agency also challenges messaging that Niktimvo provides “fast” and “lasting” responses. According to FDA, the median time to response in clinical trials was 1.5 months, with some patients taking more than five months to respond, undermining claims of rapid onset. Similarly, the median duration of response was 1.9 months, which regulators said contradicts suggestions of long-lasting benefit.

FDA further criticizes how the company presented data on organ-specific responses and symptom improvement. Visuals highlighting response rates across multiple organs were described as potentially misleading because the drug’s efficacy was evaluated based on overall response rates, not individual organ outcomes. The agency says such presentations could inflate perceptions of benefit.

In its letter, the agency requests that Incyte immediately cease or correct the violative promotional materials and provide a response within 15 working days outlining steps to address the concerns. FDA also asks the company to identify other promotional communications that may contain similar representations.